Investor Relations


 
 
     
 
 

Notice to convene the Annual General Meeting of Shareholders of Affimed N.V.
15:00 hrs CET on Tuesday 21 June 2016

 
   
 
 

Invitation notice AGM 2016

 
  Agenda and explanatory notes AGM 2016
 
  Proxy form (legal entity) AGM 2016 Word >>>
 
  Proxy form (natural person) AGM 2016 Word >>>
 
  Dutch Annual Report 2015
  In the event of any differences or inconsistencies between the text and quantitative information on this internet site and that in the original financial statements as filed at the trade register of the Chamber of Commerce, the latter shall prevail.  
 
 
Extraordinary General Meeting January 2016  
 
 
Annual Meeting June 2015  
 
 
 
 
Affimed: A Clinical-stage Biopharmaceutical Company
 
Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called Natural Killer cells, or NK-cells, and T-cells. Affimed’s proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells.

Affimed is a public company trading on the Nasdaq Global Market under the symbol "AFMD".

 
 
Stock Quote
 

 

 



  PFIC Annual Statement  
   
 
 
PFIC Annual Statement
 
     
  General FAQs  
   
 

Where are Affimed's corporate headquarters?
Affimed’s headquarters are located at Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany.

When was the company founded?
Affimed was founded in 2000.

Where is the company incorporated?
Affimed N.V. is incorporated under the laws of the Netherlands.

When did Affimed go public?
Affimed’s common shares began trading on September 12, 2014.

When is Affimed’s fiscal year-end?
Affimed’s fiscal year ends on December 31 of each year.
Affimed’s fiscal quarters end on March 31, June 30, September 30 and December 31 of each year.

How is Affimed stock traded?
Affimed’s common shares are listed on the NASDAQ Global Market under the symbol AFMD.

Who is Affimed's transfer agent?
American Stock Transfer and Trust Company LLC.

Who are Affimed's independent auditors?
KPMG AG Wirtschaftsprüfungsgesellschaft Leipzig
Address: Münzgasse 2, 04107 Leipzig
P.O. Box: Postfach 30 15 37, 04257 Leipzig
Phone: +49 341 5660-600

Where can I get the latest corporate news releases and financial reports?
Affimed’s press release archives can be viewed at: Media.
Affimed’s financial reports are available at: SEC & Financial Reports.

How can I view documents Affimed has filed with the Securities & Exchange Commission (SEC), including forms 6-K and 20-F?
Affimed’s SEC filings can be viewed at: Investor Relations or www.sec.gov .

 
  For more information contact:  
   
 

Caroline Stewart
Head Investor Relations

Phone: +1 34 73 94 67 93

IR@affimed.com
or
c.stewart@affimed.com

 

Dr. Anca Alexandru
Head of Communications

Phone: +49 62 21 64 79 33 - 41

a.alexandru@affimed.com

 
To be added to our press
release distribution system:
please klick here  
 
 
 
  Impressum Disclaimer